Solid Biosciences Inc. (SLDB)

Market Cap	437.62M
Revenue (ttm)	n/a
Net Income (ttm)	-154.08M
Shares Out	77.87M
EPS (ttm)	-2.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	734,805
Open	5.64
Previous Close	5.52
Day's Range	5.49 - 5.76
52-Week Range	2.41 - 7.37
Beta	2.54
Analysts	Strong Buy
Price Target	15.00 (+166.9%)
Earnings Date	Nov 10, 2025

About SLDB

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2018
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: SLDB
• Website: https://www.solidbio.com

Analyst Summary

According to 10 analysts, the average rating for SLDB stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 166.90% from the latest price.

Price Target

$15.0

(166.90% upside)

Analyst Consensus: Strong Buy